Is TVGN or SRZN more profitable?

Tevogen Bio has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% Surrozen -2,885.33% N/A -93.62%

Does the media refer more to TVGN or SRZN?

In the previous week, Surrozen had 4 more articles in the media than Tevogen Bio. MarketBeat recorded 6 mentions for Surrozen and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.91 beat Surrozen's score of 0.74 indicating that Tevogen Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Surrozen 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VYGR or TVGN?

In the previous week, Voyager Therapeutics had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 3 mentions for Voyager Therapeutics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.91 beat Voyager Therapeutics' score of 0.73 indicating that Tevogen Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ABOS or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is ABOS or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -136.27% -81.64% Tevogen Bio N/A N/A -468.32%

Is NBP or TVGN more profitable?

Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Tevogen Bio N/A N/A -468.32%

Does the media prefer NBP or TVGN?

In the previous week, Tevogen Bio had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Tevogen Bio and 1 mentions for I-Mab. Tevogen Bio's average media sentiment score of 0.91 beat I-Mab's score of 0.89 indicating that Tevogen Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate YDES or TVGN?

Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 1,386.99%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation and earnings, YDES or TVGN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is YDES or TVGN more profitable?

Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Tevogen Bio N/A N/A -468.32%

Does the media favor YDES or TVGN?

In the previous week, YD Bio and YD Bio both had 2 articles in the media. Tevogen Bio's average media sentiment score of 0.91 beat YD Bio's score of 0.21 indicating that Tevogen Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tevogen Bio (TVGN) Competitors

$6.72 +0.11 (+1.59%)

Closing price 03:59 PM Eastern

Extended Trading

$6.48 -0.24 (-3.64%)

As of 04:47 PM Eastern

Compare

TVGN vs. SRZN, VYGR, ABOS, NBP, and YDES

Should you buy Tevogen Bio stock or one of its competitors? Tevogen Bio's main competitors and comparable companies include Surrozen (SRZN), Voyager Therapeutics (VYGR), Acumen Pharmaceuticals (ABOS), I-Mab (NBP), and YD Bio (YDES). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tevogen Bio compare to Surrozen?

Tevogen Bio (NASDAQ:TVGN) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Tevogen Bio has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Surrozen	-2,885.33%	N/A	-93.62%

66.6% of Surrozen shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Surrozen had 4 more articles in the media than Tevogen Bio. MarketBeat recorded 6 mentions for Surrozen and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.91 beat Surrozen's score of 0.74 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tevogen Bio has higher earnings, but lower revenue than Surrozen. Tevogen Bio is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Surrozen	$3.48M	100.09	-$242.03M	-$40.55	N/A

Tevogen Bio currently has a consensus price target of $100.00, suggesting a potential upside of 1,386.99%. Surrozen has a consensus price target of $48.33, suggesting a potential upside of 61.11%. Given Tevogen Bio's higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Tevogen Bio has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Surrozen beats Tevogen Bio on 9 of the 15 factors compared between the two stocks.

How does Tevogen Bio compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Tevogen Bio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Tevogen Bio's return on equity of 0.00% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Tevogen Bio	N/A	N/A	-468.32%

In the previous week, Voyager Therapeutics had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 3 mentions for Voyager Therapeutics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.91 beat Voyager Therapeutics' score of 0.73 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tevogen Bio has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.08	-$119.72M	-$1.80	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Voyager Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 517.98%. Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 1,386.99%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Voyager Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

48.0% of Voyager Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 65.6% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Voyager Therapeutics beats Tevogen Bio on 9 of the 16 factors compared between the two stocks.

How does Tevogen Bio compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Acumen Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Tevogen Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

In the previous week, Tevogen Bio had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for Tevogen Bio and 0 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.82 beat Tevogen Bio's score of 0.91 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Very Positive
Tevogen Bio	Positive

Tevogen Bio's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
Tevogen Bio	N/A	N/A	-468.32%

Acumen Pharmaceuticals currently has a consensus target price of $7.00, suggesting a potential upside of 238.16%. Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,386.99%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 65.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Acumen Pharmaceuticals beats Tevogen Bio on 8 of the 13 factors compared between the two stocks.

How does Tevogen Bio compare to I-Mab?

I-Mab (NASDAQ:NBP) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

I-Mab currently has a consensus target price of $9.00, indicating a potential upside of 571.64%. Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,386.99%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

38.4% of I-Mab shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 65.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

I-Mab has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Tevogen Bio has lower revenue, but higher earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	39.84	-$46.27M	-$0.36	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

In the previous week, Tevogen Bio had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Tevogen Bio and 1 mentions for I-Mab. Tevogen Bio's average media sentiment score of 0.91 beat I-Mab's score of 0.89 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Tevogen Bio	N/A	N/A	-468.32%

Summary

I-Mab beats Tevogen Bio on 7 of the 13 factors compared between the two stocks.

How does Tevogen Bio compare to YD Bio?

YD Bio (NASDAQ:YDES) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 1,386.99%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, YD Bio and YD Bio both had 2 articles in the media. Tevogen Bio's average media sentiment score of 0.91 beat YD Bio's score of 0.21 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Tevogen Bio	N/A	N/A	-468.32%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Summary

Tevogen Bio beats YD Bio on 3 of the 4 factors compared between the two stocks.

Get Tevogen Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVGN vs. The Competition

Export

Metric	Tevogen Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$43.78M	$3.86B	$7.12B	$13.07B
Dividend Yield	N/A	3.63%	2.52%	14.40%
P/E Ratio	-1.45	13.52	273.57	25.81
Price / Sales	N/A	1,290.28	654.51	104.88
Price / Cash	N/A	120.99	79.75	52.18
Price / Book	-0.03	15.66	10.51	6.26
Net Income	-$26.27M	-$22.67M	$3.50B	$360.95M
7 Day Performance	-14.33%	-3.47%	-2.47%	-1.91%
1 Month Performance	-6.21%	-9.39%	-5.64%	-3.45%
1 Year Performance	-83.12%	22.39%	9.53%	2.59%

Tevogen Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVGN Tevogen Bio	1.745 of 5 stars	$6.73 +1.6%	$100.00 +1,387.0%	-83.1%	$43.78M	N/A	N/A	3	News Coverage Gap Down
SRZN Surrozen	2.5833 of 5 stars	$17.60 +6.5%	$45.00 +155.7%	+149.7%	$191.92M	$3.48M	N/A	44	News Coverage Short Interest Increase Analyst Revision
VYGR Voyager Therapeutics	2.9096 of 5 stars	$3.14 +1.9%	$16.50 +425.5%	-42.6%	$189.78M	$40.37M	N/A	141
ABOS Acumen Pharmaceuticals	3.4544 of 5 stars	$2.65 +2.3%	$7.00 +164.2%	+29.8%	$187.30M	N/A	N/A	61
NBP I-Mab	2.1724 of 5 stars	$1.59 -1.2%	$9.00 +466.0%	N/A	$186.19M	$3.89M	N/A	30	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVGN) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tevogen Bio (TVGN) Competitors

TVGN vs. SRZN, VYGR, ABOS, NBP, and YDES

How does Tevogen Bio compare to Surrozen?

Summary

How does Tevogen Bio compare to Voyager Therapeutics?

Summary

How does Tevogen Bio compare to Acumen Pharmaceuticals?

Summary

How does Tevogen Bio compare to I-Mab?

Summary

How does Tevogen Bio compare to YD Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tevogen Bio (TVGN) Competitors

TVGN vs. SRZN, VYGR, ABOS, NBP, and YDES

How does Tevogen Bio compare to Surrozen?

Is TVGN or SRZN more profitable?

Do insiders & institutionals have more ownership in TVGN or SRZN?

Does the media refer more to TVGN or SRZN?

Which has preferable earnings and valuation, TVGN or SRZN?

Do analysts prefer TVGN or SRZN?

Which has more risk and volatility, TVGN or SRZN?

Summary

How does Tevogen Bio compare to Voyager Therapeutics?

Is VYGR or TVGN more profitable?

Does the media prefer VYGR or TVGN?

Which has preferable valuation and earnings, VYGR or TVGN?

Do analysts prefer VYGR or TVGN?

Which has more risk & volatility, VYGR or TVGN?

Do institutionals and insiders have more ownership in VYGR or TVGN?

Summary

How does Tevogen Bio compare to Acumen Pharmaceuticals?

Which has more risk & volatility, ABOS or TVGN?

Which has stronger earnings & valuation, ABOS or TVGN?

Does the media prefer ABOS or TVGN?

Is ABOS or TVGN more profitable?

Do analysts recommend ABOS or TVGN?

Do insiders & institutionals hold more shares of ABOS or TVGN?

Summary

How does Tevogen Bio compare to I-Mab?

Do analysts rate NBP or TVGN?

Do institutionals & insiders believe in NBP or TVGN?

Which has more risk & volatility, NBP or TVGN?

Which has stronger earnings and valuation, NBP or TVGN?

Does the media prefer NBP or TVGN?

Is NBP or TVGN more profitable?

Summary

How does Tevogen Bio compare to YD Bio?

Do analysts rate YDES or TVGN?

Does the media favor YDES or TVGN?

Is YDES or TVGN more profitable?

Which has better valuation and earnings, YDES or TVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools